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ABSTRACT 
 DNA methylation is an epigenetic modification that plays an important role in 
gene regulation. DNA methylation varies between individuals and between tissues in the 
same individual. Many cohorts have measured DNA methylation in one or more tissues 
at hundreds of thousands of sites across the genome using methylation microarrays, and a 
standard analysis approach is to model the relationship between DNA methylation and a 
phenotype at each site and in each tissue separately. In this thesis, we explore methods 
for jointly analyzing multiple sites and/or multiple tissues. First, we propose a novel 
approach to identify differentially methylated regions (DMRs), neighboring sites in a 
single tissue associated with a phenotype, and compare our approach to two existing 
approaches to detect DMRs. We show that our method is useful when there are multiple 
sites in a region with weak or moderate associations with a phenotype. Then, we return to 
single-site analysis but evaluate methods for analyzing data from multiple tissues, 
accounting for correlation between two tissue samples from the same individual. We 
consider methods to model both the mean and variance of methylation sites as well as 
methods to model mean methylation only. In addition to evaluating existing models, we 
propose a novel random-effects meta-analysis, which is appropriate for meta-analyzing 
 
 vi 
multiple parameters from correlated studies (or tissues). We show that we have inflated 
type I error with all meta-analysis methods and methods which model the variance of 
methylation. Finally, we evaluate methods to incorporate information from multiple sites 
and multiple tissues in association tests. We examine a gene set analysis method, 
MAGENTA, which was developed for genetic association studies, and propose an 
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CHAPTER 1: Introduction 
1.1 Background 
Epigenetic modifications, changes to DNA that do not alter the underlying genetic 
code, play an important role in gene regulation1. The most commonly investigated 
epigenetic mark is cytosine DNA methylation, the addition of a methyl group to a CpG 
dinucleotide, or CpG site2. DNA methylation abnormalities have been linked to several 
environmental exposures, phenotypes, and diseases2,3. 
 DNA methylation microarrays have made it more affordable and convenient to 
assess epigenome-wide methylation levels in human tissue samples4. The recent Illumina 
MethylationEPIC BeadChip (EPIC array) measures methylation at 853,307 CpG sites5. 
Its predecessor, the Illumina Infinium HumanMethylation450 BeadChip (450k array), 
measures methylation at 482,421 CpG sites6. 
 A common approach to analyzing these data is to perform an epigenome-wide 
association study (EWAS), modeling the association between a phenotype of interest and 
methylation at each CpG site separately7-10. Because DNA methylation is tissue-specific, 
several cohorts11-16 have now collected data from the same participants in multiple 
tissues. If data from multiple tissues are available, analyses are generally performed in 
each tissue separately11-16. 
 Tissue-specific EWAS have high multiple testing burden, and there is evidence 
that individual cohorts have low power to detect the small effect sizes seen in DNA 




replicate in other cohorts and populations, suggesting that they may be true associations, 
important to understanding disease18. 
 We hypothesize that extending beyond the single-site, single-tissue EWAS 
framework can increase power to detect novel DNA methylation associations. In this 
dissertation, we explore several ways to incorporate information from multiple CpG sites 
and tissues in association tests. 
1.2 DNA methylation measurement 
 Although methylation is a binary trait at the cellular level–each CpG site is either 
methylated or not on a single DNA strand–microarrays summarize the methylation status 
at each CpG site across all DNA strands within an individual’s tissue sample. The EPIC 
and 450k arrays measure the fluorescence intensity of methylated DNA strands, M, and 
unmethylated DNA strands, U, at each CpG site in each sample19. 
 There are two common summary measures of these fluorescence intensities, Beta-
values and M-values20. Beta-values are the ratio of the methylated intensity over the total 
intensity plus a small offset γ, !
!!!!!
 , where γ is typically 100, as recommended by 
Illumina19. Beta-values are restricted between 0 and 1 and are generally interpreted as the 
percent methylation at a particular CpG site. Although Beta-values have a nice 
interpretation, their skewness, heteroscedasticity, and restricted range violate the 
assumptions of many statistical models. M-values are defined as the base 2 logit 
transformation of Beta-values, log!
!"#$
!!!"#$
, and are more appropriate for linear models, 




1.3 Study cohort 
 Throughout this dissertation, we use real DNA methylation measurements from 
the Genetics of Glucose Regulation in Gestation and Growth (Gen3G) cohort, a 
population-based cohort in Sherbrooke, Canada21. We use this data set because there are 
measurements available in multiple tissues, and the limited sample size (N<500) leads to 
low power to detect associations with traditional methods. We use real methylation data 
and simulated phenotypes in simulation studies in order to preserve the complex inter-site 
and intra-individual correlation structure of methylation data. In type I error simulations, 
we adjust for real gestational age and sex values, two common confounders in cord blood 
methylation studies22-24. 
 DNA methylation was measured in both cord blood and fetal placenta of 470 
white infants in Gen3G using the EPIC array. After quality control, there were 448 
infants with DNA methylation in placenta, 451 with cord blood methylation data, and 
444 with data for both tissues. Methylation fluorescence intensities were normalized to 
correct for technical variation using FunNorm25. Regression on Correlated Probes26 was 
used to adjust methylation Beta-values for bias introduced by the two different probe 
design technologies on the EPIC array. ComBat27 was used to correct for batch effects, 
using plate as the batch variable. After quality control, there were 791,324 CpG sites 
remaining for analysis in cord blood, 791,131 in placenta, and 790,979 in both tissues. 
1.4 Reference cohort 
 In Chapter 2, we use cord blood DNA methylation data from participants of 




Cord blood DNA methylation was measured in 485 infants using the 450k array. 
Although there are participants of multiple ethnicities in the Project Viva sample, we 
used only the 330 white infants from Project Viva as the reference cohort, as previous 
studies29,30 have shown that there are large differences in both regional and global 
methylation patterns between ethnicities. We implemented the same quality control 
procedure for the reference sample as the study cohort, Gen3G (See section 1.3). After 
quality control, there were 460,662 CpG sites remaining, of which 436,373 were present 
in the Gen3G cord blood EPIC array data. 
1.4 Differentially methylated regions 
 Differentially methylated regions (DMRs) are clusters of neighboring CpG sites 
associated with a phenotype. Searching for DMRs may increase power to detect 
associations by reducing multiple testing burden and aggregating evidence of association 
across multiple CpG sites. There are several existing methods to detect DMRs. In 
Chapter 2, we introduce these methods, discuss their strengths and limitations, propose a 
novel method to detect DMRs, and compare our approach to existing methods. 
1.5 Multi-tissue analysis 
 Analyzing DNA methylation from multiple tissues in the same individuals is 
challenging because we must take into account the correlation between tissue samples 
from the same individuals. To our knowledge, neither meta-analysis of multiple tissues 
from the same individuals nor joint analysis of multiple tissues has been proposed. In 




methods, to analyze methylation data from multiple tissues. We also propose extensions 
to existing meta-analysis methods to account the correlation between tissues. 
1.6 Gene set analysis 
 Another way to aggregate evidence of association across multiple sites is to 
search for sets of genes enriched for associations with a phenotype. In genetic association 
studies, there are many methods31-34 for identifying enriched gene sets. The most flexible 
methods are those that search for enrichment of gene sets in a user-defined list of 
associated genes, such as GOstats{Falcon:2007h}, DAVID35, and GSEAPreranked36. 
However, these methods are biased when applied to DNA methylation array data, 
because they assume that the probability of a false positive result is the same for each 
gene37. This assumption is not appropriate when analyzing DNA methylation data, in part 
because each gene can have as few as 1 or as many as thousands of CpG sites measured 
on the Illumina arrays37. In Chapter 4, we evaluate a gene set analysis method developed 
to account for bias due to technical artifacts in genome-wide association analyses, 
MAGENTA34, and propose an extension appropriate for DNA methylation array data.  
1.7 Dissertation outline 
 Throughout this dissertation, we explore several ways to incorporate information 
from multiple tissues and/or CpG sites. In Chapter 2, we evaluate methods for regional 
analysis in a single tissue. In Chapter 3, we focus on single CpG sites but incorporate 
information from two tissues. Finally, in Chapter 4, we investigate methods for detecting 





CHAPTER 2: Detecting differentially methylated regions 
2.1 Introduction 
 There are many reasons we might want to search for DMRs rather than 
differentially methylated sites. If there are multiple independent associations in a region, 
we can increase power by including all of these independent associations in one regional 
test statistic. It is also possible when analyzing microarray data that the mostly highly 
associated CpG site is not contained on the array. There are an estimated 28 million CpG 
sites in the human genome38, and the EPIC array–the largest Illumina array released to 
date–measures methylation at less than 1 million of these sites. In the case where 
methylation at the most highly associated CpG site is not measured, a regional test can 
aggregate evidence across many of the sites correlated with this unmeasured CpG site to 
detect the association. In addition, conducting regional tests can reduce multiple testing 
burden.  
 In this chapter, we evaluate the type I error and power of existing methods to 
detect DMRs and apply methods with well-controlled type I error to a real data analysis 
of birth weight. We propose a novel, flexible method, DMAnnot, and demonstrate that it 
has well-controlled type I error and increased power to detect multiple independent, weak 
effects in a region. 
2.2 Methods  
There are several existing methods to detect DMRs in methylation array data, 
including DMRcate39, Bumphunter40, comb-p41, and ProbeLasso{39-42. All of these 




must be continuous and may not be biologically meaningful. We propose a novel method, 
testing for DMRs based on annotation, and compare its performance to DMRcate and 
comb-p. We do not evaluate Bumphunter in this dissertation because it uses a 
computationally intense permutation algorithm, which is not feasible to evaluate in a 
simulation study of the entire genome. Furthermore, because we are interested in 
continuous phenotypes, we do not evaluate ProbeLasso, as it is only appropriate for 
dichotomous phenotypes. 
2.2.1 Existing methods for detecting DMRs 
 Comb-p is a flexible method for combining spatially correlated p-values in 
candidate regions41. Each p-value below a user-defined threshold starts a candidate 
region, and regions within a user-defined distance of one another are combined. 
Following the authors’ recommendation, we used 10-3 as the p-value threshold to start a 
region and combined regions with 500 bp of one another41. The type I error rate of comb-
p has not yet been rigorously evaluated. 
 DMRcate was developed specifically for detecting DMRs in methylation array 
data39. DMRcate first models the association between the phenotype and methylation at 
each site, accounting for covariates. Summary statistics of neighboring CpG sites are then 
smoothed and combined to test for DMRs in candidate regions. We use the authors’ 
recommended tuning parameters for smoothing. Candidate regions are defined as regions 
where at least 2 CpG sites have a false discovery rate (FDR) less then 0.05 in an EWAS, 




methylation be the dependent (outcome) variable, and uses M-values as the methylation 
measurement43. 
2.2.2 A novel method for detecting DMRs 
We propose a novel method to detect differentially methylated regions by 
annotation, DMAnnot. We first perform an EWAS to quantify the association between a 
continuous phenotype and methylation. Let Y be an n×1 vector of a phenotype assumed 
normally distributed, M be an n×1 vector of methylation M-values, and X be an n×p 
matrix of covariates. We model the association between methylation and the phenotype at 
each CpG site using the following model: 




We use the z-score from this model, 𝑧 = !!
!" !!
, to quantify the association 
between the phenotype and methylation at each site. It has been shown that under the null 
hypothesis of no association, the vector of z-scores for any set of s CpG sites, zs, follows 
asymptotically the multivariate normal distribution with mean 0 and covariance 𝛴, where 
𝛴 is the s×s partial pairwise correlation matrix between CpG sites, accounting for all 
covariates in the model44. It follow that, 𝑧!!𝛴!!𝑧!~𝜒! with s degrees of freedom. 
If any of the s CpG sites are perfectly correlated, 𝛴 is singular and the 𝜒! statistic 
cannot be computed. If there is a high degree of collinearity among the s CpG sites, even 
if none are perfectly correlated, the calculation of the test statistic will be unstable, so 




This high collinearity can occur when s is small and pairwise correlations are high, but 
also when s is large and pairwise correlations are weak to moderate. Therefore, pruning 
sets of CpG sites based on pairwise correlation, as is often done in genetic contexts45, is 
not sufficient. We use the correlation matrix condition number, 𝜅 = 𝛴!! ⋅ ‖𝛴‖, to 
assess the degree of collinearity. If all s CpG sites are independent, 𝜅 = 1, and more 
collinearity among CpG sites results in a higher 𝜅. We propose pruning out CpG sites 
until the condition number of 𝛴 is below a pre-defined threshold before calculating the 
test statistic, and we evaluate 4 possible thresholds: 5, 10, 20, and 100. For a set of 2 CpG 
sites, these 𝜅 thresholds correspond to pairwise Pearson correlation thresholds of 
approximately 0.67, 0.82, 0.90, and 0.98, respectively. To put this in perspective, a 
pairwise correlation of more then 0.7 is often seen as evidence of collinearity among 
linear regression predictors46. We use the trim.matrix() function in the “subselect” R 
package, which implements Jolliffe’s selection method47, to iteratively remove CpG sites. 
Figure 2.3 shows an illustration of this method.  
This 𝜒! test can be applied to any set of s CpG sites. We group CpG sites into sets 
by genes and CpG islands, areas of the genome with more CpG sites than expected by 
chance. In light of evidence that the relationship between methylation and gene 
expression depends on the location within the gene–increased methylation of promoters 
is generally associated with downregulation of gene expression while increased 
methylation of gene bodies is generally associated with upregulation of gene 
expression48–we divide genes into 4 subcategories. We conduct a separate 𝜒! test for 




start site (TSS) to 1500 base pairs (bp) upstream, so we perform a maximum of four 𝜒! 
tests for one gene. For CpG islands, we conduct only one 𝜒! test per CpG island, which 
includes the CpG island, shores, and shelves (defined as the island boundaries +/- 4000 
bp)6. We use a Bonferroni correction (at α=0.05) to adjust for the 99,016 gene and island 
regions on the EPIC array tested. This is a conservative approach, as many of the CpG 
islands overlap with a gene category. 
Calculating the partial correlation between CpG sites across the entire epigenome 
quickly becomes computationally intense when there are many covariates. The small 
effect sizes we see in epigenetic studies make it plausible that the difference between the 
partial and marginal correlation of two CpG sites is negligible, and that the marginal 
correlation is sufficient for estimating 𝛴. Furthermore, it is common in genetic studies to 
use publicly available data of the same ancestry as the study cohort to estimate marginal 
correlation between genetic variants when individual data from the study cohort are not 
available17,32,49, but this approach has not been evaluated for epigenetic studies to our 
knowledge. We evaluate 3 estimations of 𝛴: the partial correlation between CpG sites in 
the study sample accounting for all model covariates (Gen3G partial), the marginal 
correlation between CpG sites in the study sample (Gen3G marginal), and the marginal 





Figure 2.1 DMAnnot algorithm  
 
Illustration of the DMAnnot algorithm for two regional tests within a gene. 
2.2.3 Simulation design 
 To evaluate type I error, we simulated i=1,..,200 phenotypes, Yi, associated with 
two common confounders, gestational age and sex, but not associated with DNA 
methylation. This resulted in over 158.3 million single CpG site tests (790,324 sites per 
simulation) and 19.8 million regional tests (99,016 annotations per simulation) to 
evaluate type I error. In the Gen3G sample, gestational age explains 14.2% of the 




in birth weight after adjusting for gestational age. We used these values to simulate 
phenotypes associated with both gestational age and sex. We simulated Yi using the 
following equation: 
𝑌! = 𝛽!"# ⋅ 𝑆𝑒𝑥 + 𝛽!" ⋅ 𝑔𝑒𝑠𝑡𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑔𝑒 + 𝑒! , 
where  𝛽!"# =
0.016
𝑉𝑎𝑟 𝑠𝑒𝑥  , 𝛽!" =
0.142
𝑉𝑎𝑟 𝑔𝑒𝑠𝑡𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑔𝑒   , 
𝑒!~𝑁 0,𝜎! ,   and   𝜎! = 1− 0.142− 0.16 = 0.842 
 Each of the DMR methods we compared use EWAS summary statistics as input. 
For our method and comb-p, we performed the EWAS using a standard multiple linear 
regression model. We modeled the association between these null phenotypes and 
methylation M-value at each CpG site, Mj, using the following model: 
 𝐸 𝑌!|𝑀! ,𝑋 =  𝛽! + 𝛽! ⋅𝑀! +  𝛽!"# ⋅ 𝑆𝑒𝑥 + 𝛽!" ⋅ 𝐺𝑒𝑠𝑡𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑔𝑒 
For DMRcate, the EWAS is performed using limma, an R package designed to 
implement linear models in the context of gene expression microarrays. As noted earlier, 
DMRcate requires that methylation be the dependent variable, so the EWAS model 
implemented is: 
𝐸 𝑀!|𝑌! ,𝑋 =  𝛽! + 𝛽! ⋅ 𝑌! +  𝛽!"# ⋅ 𝑆𝑒𝑥 + 𝛽!" ⋅ 𝐺𝑒𝑠𝑡𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑔𝑒 
For each simulation, we calculated the epigenome-wide error rate for the EWAS 
and DMAnnot at various significance levels. We then calculated the mean type I error 
rate across all 200 simulations and compared this to the expected type I error rate. 
Because comb-p and DMRcate both use the data to define the number of and boundaries 




methods. Therefore, rather than calculating a type I error rate, we compare the 
distribution of the number of false positive DMRs identified across 200 simulations of 
these methods to DMAnnot.  
We then simulated i=1,…,200 phenotypes, Yi, each under 6 scenarios in order to 
evaluate the power of methods with well-controlled type I error. In each scenario, the 
phenotypes were simulated to be associated with sex, gestational age, and 2 of the 8 CpG 
sites in a CpG island on chromosome 7 (chr7: 55,072,266-55,072,622). Each CpG site 
independently explained either 2% (weak association, partial R2=0.02) or 3% (moderate 
association, partial R2=0.03) of the variation in the phenotype. We chose three pairs of 
CpG sites, which were weakly (r=0.10), moderately (r=0.39), or strongly (r=0.86) 
correlated with each other. Table 2.1 shows the associated CpG sites, strength of 
association, and correlation between associated sites for each scenario. We simulated Yi 
using the following equation: 
𝑌! = 𝛽!"# ⋅ 𝑆𝑒𝑥 + 𝛽!" ⋅ 𝑔𝑒𝑠𝑡𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑔𝑒 + 𝛽! ⋅ 𝐶𝑝𝐺! + 𝛽! ⋅ 𝐶𝑝𝐺! + 𝑒! , 
where  𝛽!"# =
0.016
𝑉𝑎𝑟 𝑠𝑒𝑥  , 𝛽!" =
0.142








  𝑒!~𝑁 0,𝜎! ,      and       𝜎! = 0.842− 2 ⋅ partial 𝑅! 
In order to adjust for technical covariates that may be correlated with our 




components analysis and included the first 5 principal components (PCs) in our EWAS 
models:  




For each scenario, we calculated the proportion of simulations where each method 
identified a significant association at any position(s) in the CpG island, between 
55,064,266 and 55,076,622 bp on chromosome 7. We then computed an exact 95% 
binomial confidence interval around these proportions. 
Table 2.1 Power simulation scenarios 
Scenario CpG 1 CpG 2 Correlation Partial R2 
1 cg07313064 cg00832581 0.10 0.02  
2 cg07313064 cg00832581 0.10 0.03  
3 cg07313064 cg09508476 0.39 0.02  
4 cg07313064 cg09508476 0.39 0.03  
5 cg07313064 cg13490352 0.86 0.02  
6 cg07313064 cg13490352 0.86 0.03  
2.2.4 Real data analysis 
 We implemented all methods with well-controlled type I error in a real data 
analysis in Gen3G, testing for DMRs associated with birth weight. We included 
gestational age and sex as covariates. Table 2.2 shows some basic characteristics of the 
451 Gen3G infants included in the model.  
Table 2.2 Characteristics of Gen3G infants 







Gestational age (weeks) 39.5±1.0 






2.3.1 Type I error simulation results 
 Table 2.3 shows the observed error rate of the EWAS and DMAnnot compared to 
the expected error rate for several significance levels. Type I error was always well 
controlled for DMAnnot when using the partial correlation from the study cohort to 
estimate 𝛴. At the lowest significance level, α=1×10-6, type I error was inflated for 
DMAnnot when using the marginal correlation in the study cohort to estimate 𝛴 without 
any CpG site pruning. However, the type I error was well controlled with even the least 
stringent (κ <100) pruning criteria. This is not surprising, because we expect small 
differences in the partial and marginal correlations, and when there is very high 
collinearity in a region (κ >100), the test statistic will be sensitive to these small 
differences.  
 Type I error was severely inflated at all significance levels for all pruning 
methods when estimating 𝛴 from the reference cohort. At the α=1×10-6 significance level, 
using the most stringent CpG site pruning criteria (κ <5), we observed an error rate 
almost 50 times as large as expected. This suggests that it is not appropriate to estimate 
correlation between CpG sites using an external reference cohort, even if the samples are 
of the same ethnicity. 
 While the percentage of simulations with any false positives for DMRcate was 
low (2%), the maximum number of false positive regions identified in a single simulation 










Table 2.3 Ratio of mean observed type I error rates to expected type I error rates 
for DMR methods  
Method α 5×10-2 1×10-2 1×10-3 1×10-4 1×10-5 1×10-6 
Single site EWAS 0.96 0.90 0.84 0.77 0.63 0.53 
DMAnnot,  
Σ= Gen3G partial        
No pruning 0.96 0.90 0.83 0.75 0.60 0.61 
κ <100 0.96 0.91 0.83 0.75 0.60 0.61 
κ <20 0.96 0.91 0.84 0.76 0.62 0.56 
κ <10 0.96 0.92 0.84 0.78 0.67 0.71 
κ <5 0.96 0.92 0.87 0.80 0.75 0.61 
DMAnnot,  
Σ= Gen3G marginal       
No pruning 0.97 0.92 0.86 0.81 0.88 2.12 
κ <100 0.97 0.92 0.86 0.79 0.72 0.81 
κ <20 0.97 0.92 0.86 0.79 0.67 0.61 
κ <10 0.96 0.92 0.86 0.79 0.70 0.71 
κ <5 0.96 0.93 0.87 0.80 0.81 0.76 
DMAnnot, 
Σ=Reference marginal       
No pruning 3.37 8.96 45.95 278.82 1868.88 13406.11 
κ <100 3.30 8.51 40.73 224.76 1345.01 8515.68 
κ <20 2.60 5.40 18.22 70.39 296.71 1341.98 
κ <10 1.99 3.43 8.72 25.70 84.70 303.35 
κ <5 1.45 2.02 3.69 7.75 18.39 48.27 
 
Ratio of mean observed type I error rates to expected type I error rates for EWAS and 
DMAnnot at various significance levels, α. Mean observed error rates were calculated 






Table 2.4 Distribution of the number false positive DMRs by method 
Method Min Q1 Med Q3 Max % Any FP 
DMAnnot,  
Σ= Gen3G partial      
 
No pruning 0 0 0 0 1 3% 
κ <100 0 0 0 0 1 3% 
κ <20 0 0 0 0 1 3% 
κ <10 0 0 0 0 1 4% 
κ <5 0 0 0 0 1 4% 
DMAnnot,  
Σ= Gen3G marginal      
 
No pruning 0 0 0 0 2 15% 
κ <100 0 0 0 0 2 4% 
κ <20 0 0 0 0 1 3% 
κ <10 0 0 0 0 1 4% 
κ <5 0 0 0 0 1 4% 
DMAnnot, 
Σ=Reference marginal      
 
No pruning 634 838.8 988.5 1170 2809 100% 
κ <100 314 463 585 722 2355 100% 
κ <20 15 50.75 74 99 633 100% 
κ <10 2 9 13 22 191 100% 
κ <5 0 1 2 3.25 37 76% 
DMRcate 0 0 0 0 2097 2% 
comb-p 0 0 1 2 479 63% 
 
The first five numeric columns show the minimum (Min), first quartile (Q1), median 
(Med), third quartile (Q3), and maximum (Max) number of false positives across 200 
epigenome-wide simulations. The last column represents the percentage of simulations 
with any false positives (FP). False positives are defined as DMRs with p<0.05, after 





2.3.2 Power simulation results 
 When the 2 associated CpG sites were either weakly or moderately correlated 
with each other (scenarios 1-4), DMAnnot had higher power than DMRcate and the 
single-site EWAS for both correlation estimates and all CpG pruning thresholds. When 
the associated CpG sites were strongly correlated (scenarios 5 and 6), DMAnnot had 
lower power than DMRcate when using the most stringent CpG site pruning (κ <5) but 
higher power when using any other κ threshold. In all 6 scenarios, the single-site EWAS 
had higher power than DMRcate (Figure 2.1). This is likely because DMRcate requires at 
least 2 sites in a region to have an EWAS FDR less than 0.05 to define a region. 
 In general, the power of DMAnnot decreased with more stringent CpG site 
pruning. This decrease was most severe when the 2 associated CpG sites were highly 
correlated with each other. This is because when the 2 associated CpG sites are highly 
correlated, they both contribute to the high region collinearity, and one or both are likely 
to be removed from the χ2 test using Jolliffe’s iterative subset selection method47. 
Unsurprisingly, DMAnnot has low power to detect an associated region if the CpG sites 
with the strongest associations are not included in the test. 
 Our method was useful for aggregating independent associations. In the scenario 
with 2 weakly correlated, weak associations, the EWAS identified the associated region 
in 2% of simulations, while DMAnnot identified the associated region in 3.5% to 11% of 
simulations, depending on the correlation estimate and κ threshold. In the scenario with 2 
weakly correlated, moderate associations, the EWAS identified the associated region in 




Figure 2.2 Power to detect associated DMR on chromosome 7  
 
Estimated power to detect any association in a CpG island on chromosome 7 
(chr7:55072266-5507262), where 2 out of 8 CpG sites are associated with the phenotype. 
The 2 associated CpG sites were weakly (r=0.10), moderately (r=0.39), or strongly 
(r=0.86) correlated with each other, and both CpG sites had either a weak (partial 
R2=0.02) or moderate (partial R2=0.03) effect on the phenotype. DMAnnot was run with 
multiple CpG site pruning thresholds and 2 different correlation estimates (the partial and 




2.3.3 Real data analysis  
The EWAS did not identify any significantly associated CpG sites after adjusting 
for multiple testing using a Bonferroni correction, but both regional methods identified 
associated loci. Table 2.5 shows all significant DMRs at the α=0.05 significance level, 
after adjusting for multiple testing. There was no overlap in DMRs identified by 
DMAnnot and DMRcate. 
 DMRcate identified 4 DMRs associated with birth weight. Of these DMRs, 2 
were located in genes with previously identified associations between DNA methylation 
and birth weight, LTA on chromosome 650 and PEG10 on chromosome 751.  
DMAnnot identified between 2 and 4 DMRs, depending on the correlation 
estimate used and the CpG pruning method. Pruning CpG sites reduced the number of 
DMRs detected. Without pruning, we identified 4 DMRs when estimating Σ using the 
marginal correlation and 3 DMRs using the partial correlation. With CpG site pruning at 
any κ threshold, the results were the same for both estimates of Σ. Of the 4 DMRs 
identified by our method, 3 were located in 2 genes previously identified as associated 
with birth weight and prenatal malnutrition, respectively: PIM1 on chromosome 6 52 and 






Table 2.5 DMRs associated with birth weight in a real data analysis 
Region 
name 
Chr Start End Methods identifying DMR 
RFTN1 body 3 16361589 16531500 DMAnnot, Σ=marginal, no pruning 
 
- 6 31539973 31540136 DMRcate 
 
PIM1 TSS 6 37136661 37137824 DMAnnot, Σ=partial, all pruning method 
DMAnnot, Σ=marginal, all pruning methods 
CpG island 6 37137070 37139434 DMAnnot, Σ= partial, all pruning methods 
DMAnnot, Σ= marginal, all pruning methods 
 
- 7 94285642 94286362 DMRcate 
 
IFITM1 TSS 11 312518 313624 DMAnnot, Σ= partial, no pruning or κ <100 
DMAnnot, Σ= marginal, no pruning or κ <100 
 
- 11 2890587 2890670 DMRcate 
 
- 16 8806359 8807043 DMRcate 
DMRs associated with birth weight, by chromosome (Chr) and start position (Start). 
Regions identified by DMRcate do not have region names. All DMAnnot correlation 
matrices (partial or marginal correlation) were estimated from the study cohort, Gen3G. 
 
2.4 Discussion 
We demonstrated that the type I error rate of DMAnnot is well controlled when 
estimating correlation between sites using the study cohort, and that estimating the 
marginal correlation is sufficiently accurate even in the presence of confounders. 
Although reference cohorts can give reliable estimates of correlation between genetic 
variants, estimating correlation between CpG sites from a reference sample of the same 
ethnicity greatly increased the type I error, indicating that this approach may not be 




The type I error rate of DMRcate was generally well controlled, but in one 
simulation where EWAS test statistics were inflated, DMRcate identified over 2,000 false 
positive regions. Neither DMAnnot nor the single-site EWAS identified a large number 
of associations in this simulation. This suggests that DMRcate may be particularly 
sensitive to inflation in type-I error rate of the input EWAS. This is perhaps due to the 
difference in multiple testing corrections. We used a Bonferroni correction to adjust for 
multiple testing in DMAnnot and the EWAS, while DMRcate uses a less conservative 
FDR.  
We found that the false positive rate of comb-p was extremely inflated. In 63% of 
the simulations we performed, comb-p identified at least one false positive DMR. In one 
simulation, comb-p identified over 600 false positive DMRs.   
 The power of DMAnnot, and the number of DMRs detected in the real data 
analysis, decreased as the κ threshold for pruning CpG sites decreased. Therefore, we 
recommend a κ threshold of 100, which had the highest power of any pruning threshold 
and well controlled type I error. Using this threshold, DMAnnot had higher power than 
DMRcate in all 6 scenarios.  
In an EWAS of real birth weight data, there were no significantly associated CpG 
sites in cord blood after adjusting for multiple testing, but both our method and DMRcate 
identified 4 DMRs associated with birth weight. Each method identified 2 DMRs with 
previous evidence of association with birth weight or prenatal nutrition, although these 




DMRcate has higher power to detect associations than DMAnnot. Further work is needed 
to investigate this. 
Our method appears to be most powerful when aggregating evidence of 
association across many weakly or moderately correlated CpG sites in a region. This may 
be most suitable for analyzing complex traits, where we expect to see many weak 
associations across the genome54. 
Furthermore, our method can be applied to any pre-defined sets of CpG sites. 
Although we grouped CpG sites by genes and CpG islands, which are continuous 
segments of the genome defined by a start and end position on a single chromosome, 
DMAnnot is not restricted to continuous regions of the genome like DMRcate and comb-
p. This will be particularly useful as more complex regional annotations, such as those in 
the 3D Genome Browser55, become available. In the future, we plan to explore grouping 





CHAPTER 3: Multi-tissue analysis 
3.1 Introduction 
 Analyzing DNA methylation data measured in multiple tissues from the same 
individuals presents several challenges. The primary challenge is that the observations are 
not independent, so our model must account for the correlation between tissue samples 
from the same individual. Furthermore, it may not be reasonable to assume that the 
estimate of effect is the same in all tissues, or that the effects of covariates on methylation 
are the same in all tissues.  
In this chapter, we evaluate 5 methods for analyzing the association between 
methylation at a single CpG site and a phenotype of interest across multiple tissues. 
Existing methods make several assumptions that may not be reasonable for multi-tissue 
DNA methylation analyses. All existing methods assume that the effect size of the 
phenotype of interest is the same in both tissues, and some further assume that the 
covariates and/or covariate effect sizes are the same in both tissues. We propose a novel 
method for meta-analyzing multiple parameters from correlated studies (or tissues), 
which does not make any of these assumptions. We demonstrate its validity when studies 
are independent and compare its performance to 4 existing methods in a multi-tissue 
DNA methylation simulation study.   
3.2 Methods 
. In addition to the standard linear model framework, we consider beta 
regression{56. Beta regression has been proposed for methylation Beta-values because it 




associations between a phenotype and both the mean and variance of DNA methylation57-
59. Figure 2 shows some characteristics of the 5 methods we evaluate: a linear mixed 
effects (LME) model, fixed effects meta-analysis of linear regression models (FEL), 
Gaussian copula beta regression (GCB), fixed effects meta-analysis of beta regression 
models (FEB), and random effects meta-analysis of beta regression models (REB). In all 
methods, methylation is the dependent variable. For the linear models, we use M-values 
as the dependent variables, and for the beta regression models, we use Beta-values. In all 
3 beta regression models we test for an association between the phenotype and both mean 
and variance of methylation, while in the linear models we test for an association 
between the phenotype and mean methylation only. The 3 meta-analysis methods allow 
for different covariate effects in each tissue, while the 2 joint models assume the same 
covariate effects. Finally, all methods except REB assume that the effect of the 
phenotype of interest on methylation is the same in all tissues. We develop and apply a 
novel method for meta-analyzing multiple parameters from correlated studies to the REB 
model, but this method is generalizable to any model with approximately normally 





Figure 3.1 Summary of multi-tissue methods  
 
 
3.2.1 Linear mixed effects model 
 Let n be the sample size in each tissue, Y be a 2n×1 phenotype vector, M be a 
2n×1 vector of methylation M-values, and X be a 2n×p matrix of covariates, including 
gestational age, sex, and tissue (cord blood or placenta). For each individual i and tissue t, 
we model the following for a single CpG site: 
𝑀!" = 𝛽! + 𝛽!𝑌!" + 𝛽!𝑋!,!"
!
!!!
+ 𝑠! + 𝑒!" ,  
where 𝑒!!×!~𝑁 0,𝜎!!  and 𝑠!×! ~𝑁(0,𝜎!!) 
In our case, each individual has the same phenotype and covariate values (sex, 
gestational age) for each tissue, but tissue-specific covariates (e.g. technical covariates) 
may be included. We include only a random intercept, si, in the model because we have 





3.2.2 Fixed effects meta-analysis of linear regression models 
 Let Y be an n×1 phenotype vector, M be an n×1 vector of methylation M-values 
in a single tissue, and X be an n×p matrix of covariates. In each tissue, we perform an 
EWAS using the following model: 




We implement O’Brien’s method60 to meta-analyze the phenotype z-scores, 
𝑧 = !!
!" !!
, in the tissue-specific linear regression models. Let W be a t×1 vector of 1’s, 
where t is the number of tissues. Then,  
𝑊!𝛴𝑧~𝑁(0,𝑊!𝛴𝑊) 
For each CpG site, we estimate 𝛴 using the observed intra-individual correlation 
of methylation M-values. 
3.2.3 Beta regression 
 Beta regression is a natural candidate for modeling DNA methylation data, as it is 
meant for outcomes restricted between 0 and 1 and allows us to model heteroscedasticity. 
The beta distribution density is usually parameterized by  
𝑓 𝑥;𝛼,𝛽 =
𝛤 𝑎 + 𝑏
𝛤 𝑎 𝛤 𝑏 𝑥
!!! 1− 𝑥 !!!, where 0<x<1, a>0, b>0 
 Ferrari and Cribari-Neto61 proposed an alternate parameterization in terms of the 
mean, 𝜇 = !
!!!




𝑉𝑎𝑟 𝑋 = ! !!!
!!!
. In beta regression, both 𝜇 and 𝜙 can be modeled as a function of some 
independent variables through link functions62. 












Because it’s been shown that beta regression is sensitive to outliers58, we removed 
outlier methylation values. As suggested in previous methylation studies63, we defined 
outliers using the Tukey method, where any value less than the first quartile minus three 
times the interquartile range or greater than the third quartile plus three times the 
interquartile range is considered an outlier64. 
3.2.4 Gaussian copula beta regression 
 Song et al.65 proposed a method for jointly analyzing correlated beta regression 
models using Gaussian copulas. We use this method to jointly analyze our two tissue-
specific beta regression models described in 3.2.3. We assume an exchangeable intra-
individual correlation. However, because we only have two tissues, all intra-individual 
correlation structures are the same. Jointly analyzing more than 2 tissues would be 




3.2.5 Fixed effects meta-analysis of beta regression models 
 Because we model the relationship between the phenotype and both the mean and 
precision of methylation in each tissue, we have two parameters from each tissue to 
include in a meta-analysis. Becker and Wu66 proposed described a multivariate 
generalized least squares (GLS) approach for meta-analyzing p parameters each from k 




 be the p×1 vector of true effect sizes, Wkp×p be a stack of k 





𝛴 = 𝐶𝑜𝑣 𝑏 . They proposed the following model: 
𝑏!"×! =𝑊!"×!𝛽!×! + 𝑒!"×!, where 𝑒~𝑁(0!"×!,𝛴!"×!") 
The fixed effects GLS estimator for this model is 𝛽! = (𝑊!𝛴!!𝑊)!!𝑊!𝛴!!𝑏, 
and 𝐶𝑜𝑣(𝛽!) = (𝑊!𝛴!!𝑊)!!. When studies are independent,  
Σ =
𝛴!! 0 ⋯ 0
0 𝛴!! 0 0
⋮ 0 ⋱ ⋮
0 0 ⋯ 𝛴!!
, where 𝛴!!  is the covariance matrix for the ith cohort 
This estimator was derived for independent studies, but holds for any covariance 
matrix Σ. However, the best approach to estimate the correlation between parameters 
from different studies has not been investigated. Yang et al.67 investigated a similar 
question when meta-analyzing multiple genome-wide association studies (GWAS) of 




genome-wide summary statistics of each phenotype to compute the covariance between 
phenotype coefficients: 
𝐶𝑜𝑣 𝑧!!!"# !, 𝑧!!!"# ! = 𝑆𝐷(𝑧!!!"# !) ⋅ 𝑆𝐷(𝑧!!!"# !) ⋅ 𝐶𝑜𝑟(𝑧!!!"# !, 𝑧!!!"# !) 
In Yang et al.’s case, the genetic measure (genotype) was the same in both models 
and the two phenotypes were correlated. In our case, the phenotype is the same for both 
tissues and the two genetic measures (DNA methylation) are correlated. We are 
interested in estimating the covariances between the mean and precision parameters 
across tissues: 𝐶𝑜𝑣(𝛽!"#$ !"##$ ,𝛽!"#$%&'#), 𝐶𝑜𝑣(𝛽!"#$ !"##$ , 𝛾!"#$%&'#), 
𝐶𝑜𝑣(𝛾!"#$ !"##$ ,𝛽!"#$%&'#), and  𝐶𝑜𝑣(𝛾!"#$ !"##$ , 𝛾!"#$%&'#). Because these covariances 
depend on the intra-individual correlation at the CpG site of interest, it is not appropriate 
to calculate one global correlation estimate for all CpG sites. We propose binning CpG 
sites by intra-individual correlation, rID, and calculating the correlation of summary 
statistics within each bin rather than genome-wide. Because negative intra-individual 
correlation is rare, we propose 1 bin for all CpG sites with negative intra-individual 
correlations. For CpG sites with positive intra-individual correlations, we create 10 bins: 
𝑟!" ∈ 0,0.1 , 𝑟!" ∈ 0.1,0.2 ,… , 𝑟!" ∈ [0.9,1].  
We use a Wald χ2 test of the summary 𝛽 vector to determine whether a CpG site 
is associated with the phenotype of interest. 
3.2.6 Random effects meta-analysis of beta regression models 
 In the FEB model, our underlying assumption is that the effect size of the 




is heterogeneity in effect sizes across tissues, we can model this heterogeneity by 
introducing a random effect, δ, into the model:   
𝑏!"×! =𝑊!"×!𝛽!×! + 𝛿!"×! + 𝑒!"×!, 




, 𝛿!,… , 𝛿!
𝑖𝑖𝑑
~ 𝑁 0!×!,𝑇!×! , 
The summary estimator for this model is 𝛽! = (𝑊!𝛺!!𝑊)!!𝑊!𝛺!!𝑏, where 
𝛺!"×!" = 𝐶𝑜𝑣(𝑏) = 𝛴!"×!" + 𝐼!×! ⊗ 𝑇!×! and 𝐶𝑜𝑣(𝛽!) = (𝑊!𝛺!!𝑊)!!68.  
Chen et al.68 proposed a method of moments estimator for the between-study 
covariance matrix, T, using the fixed effects estimator, 𝛽!. Chen et al. show that 
𝐸 (𝑏! − 𝛽!)(𝑏! − 𝛽!)′!!!!  is a function of T and can be used to derive an unbiased 
method of moments estimator. However, the derivation of this estimator requires that the 
cohorts be independent. When studies are independent,  
Σ =
𝛴!! 0 ⋯ 0
0 𝛴!! 0 0
⋮ 0 ⋱ ⋮
0 0 ⋯ 𝛴!!
, where 𝛴!!  is the covariance matrix for the ith cohort 
This matrix, like all block diagonal matrices, has the convenient property that 
Σ!! =
𝛴!!!! 0 ⋯ 0
0 𝛴!!!! 0 0
⋮ 0 ⋱ ⋮
0 0 ⋯ 𝛴!!!!
 
  The derivation of Chen et al.’s method of moments estimator depends on this 
property of block diagonal matrices. Therefore, it is not appropriate for meta-analyzing 




propose an extension to this method, which is appropriate for correlated studies, using the 
same framework as Chen et al.  
























 Let 𝛬 =𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!. Without assuming independence of studies, we 
show that  








We propose estimating T numerically to find 𝑇 such that we minimize 
𝑏! − 𝛽! 𝑏! − 𝛽!
!




 However, minimizing this function with respect to T may yield an estimated 
covariance matrix which is not positive definite. In order to ensure our estimate of T is 
positive definite, we use the Cholesky decomposition of T, 𝑇 = 𝐿𝐿′, and find 𝐿 such that 
we minimize 
𝑏! − 𝛽! 𝑏! − 𝛽!
!




The full derivation of this estimator can be found in the Appendix. As with the 
fixed effects meta-analysis, we use a Wald χ2 test of the summary estimate, 𝛽!, to 




3.2.7 Summary statistics simulation 
 We replicated the simulation study performed by Chen et al. in order to evaluate 
our method under the assumption of independent studies68. We simulated summary 
statistics for 10 studies with 2 parameter estimates each. For each simulation, 100 random 
within-study variances were drawn from a χ2 distribution with 1 degree of freedom. χ2 
values greater than 2.7 or less than 0.016 were discarded, and 20 within-study variances 
were randomly sampled from the remaining values. χ2 values were sorted and assigned in 
pairs, such that the largest two variances were assigned to study 1, the next largest two 
variances were assigned to study 2, and so on. The within-study correlation, the 
correlation between two parameters from the same study, was set to 0.2. The within-study 
correlation was then used to calculate the covariance between parameters in each study 
from these variances. 
𝛴!!,!" = 𝛴!!,!" = 0.2 ⋅ 𝛴!!,!! ⋅ 𝛴!!,!! = 0.2 ⋅ 𝑉𝑎𝑟 𝛽!,! ⋅ 𝑉𝑎𝑟  𝛽!,! ,  
where 𝑉𝑎𝑟 𝛽!,!  denotes the 𝑗!! within-study variance for study 𝑖 
 The random effect covariance (referred to as the “between-study covariance” by 
Chen et al.), T2×2, was calculated from 𝐼!! and 𝐼!!, the proportions of variation in the first 












𝐼!! and 𝐼!! were set to 0.2, 0.5, or 0.8, resulting in 9 scenarios with independent 
studies. The random effect correlation was set to 0.2 and used to calculate T12 and T21. 
𝑇!" = 𝑇!" = 0.2 ⋅ 𝑇!! ⋅ 𝑇!! 
There were only two small differences between our simulation and Chen et al.’s 
original simulation: both the within-study and random effect correlation were set to 0.2 
(Chen et al. evaluated 0.2 and 0.8 for both of these correlations), and we introduced 
dependence between studies as an extra variable for our method only, so 𝛴!" was not 
equal to 0 for all 𝑖 ≠ 𝑗.  
We quantified the dependence between studies using the correlation between 
estimates of the same parameter from different studies (e.g. 𝐶𝑜𝑣(𝛽!,!,𝛽!,!)). We refer to 
this value as the between-study correlation and consider 4 values: 0 (independent 
studies), 0.2, 0.5, or 0.8. This left only one correlation to estimate: the correlation 
between estimates of different parameters from different studies (e.g. 𝐶𝑜𝑣(𝛽!,!,𝛽!,!)). 
Given the random effect correlation, 0.2, and the between-study correlation, we can 
calculate the range of possible values for the correlation between estimates of different 
parameters from different studies. Given any three variables–A, B, and C–the partial 
correlation between A and B, accounting for C is: 
𝜌!"|! =
𝜌!" − 𝜌!"𝜌!"
1− 𝜌!"! 1− 𝜌!"!  
,−1 ≤ 𝜌!"|! ≤ 1 
It follows that  
−1 ≤  
𝜌!" − 𝜌!"𝜌!"





− 1− 𝜌!"! 1− 𝜌!"! ≤ 𝜌!" − 𝜌!"𝜌!" ≤ 1− 𝜌!"! 1− 𝜌!"!  
𝜌!"𝜌!" − 1− 𝜌!"! 1− 𝜌!"! ≤ 𝜌!" ≤ 𝜌!"𝜌!" + 1− 𝜌!"! 1− 𝜌!"!  
𝜌!" ∈ 𝜌!"𝜌!" − 1− 𝜌!"! 1− 𝜌!"! ,𝜌!"𝜌!" + 1− 𝜌!"! 1− 𝜌!"!  
This means that if we know 𝜌!"  and 𝜌!" , we can calculate a range of possible 
values for 𝜌!", centered at 𝜌!"𝜌!" . Note that the within-study correlation is the 
correlation between two estimates of different parameters from the same study (𝜌!") and 
the between-study correlation is the correlation between two estimates of the same 
parameter from different studies (𝜌!"). Therefore, we calculated the correlation between 
different parameters in different studies by multiplying the within-study correlation, 0.2, 
by the between-study correlation.  
A vector of effect sizes, b20×1, was drawn from a multivariate normal distribution 
with mean 0 and covariance matrix 𝛴 + 𝐼!"×!"⊗ 𝑇. We performed 1000 simulations per 
scenario. Because Chen et al.’s method is not appropriate for correlated studies, we 
evaluated only the 9 scenarios where between-study correlation was 0 for Chen et al.’s 





Table 3.1 Power scenarios for summary statistics simulation  
𝑰𝟏𝟐 𝑰𝟐𝟐 
Between-study 
correlation Methods Evaluated 
0.2 0.2 0 Chen, Lent 
  0.2 Lent 
  0.5 Lent 
  0.8 Lent 
0.2 0.5 0 Chen, Lent 
  0.2 Lent 
  0.5 Lent 
  0.8 Lent 
0.2 0.8 0 Chen, Lent 
  0.2 Lent 
  0.5 Lent 
  0.8 Lent 
0.5 0.2 0 Chen, Lent 
  0.2 Lent 
  0.5 Lent 
  0.8 Lent 
0.5 0.5 0 Chen, Lent 
  0.2 Lent 
  0.5 Lent 
  0.8 Lent 
0.5 0.8 0 Chen, Lent 
  0.2 Lent 
  0.5 Lent 
  0.8 Lent 
0.8 0.2 0 Chen, Lent 
  0.2 Lent 
  0.5 Lent 
  0.8 Lent 
0.8 0.5 0 Chen, Lent 
  0.2 Lent 
  0.5 Lent 
  0.8 Lent 
0.8 0.8 0 Chen, Lent 
  0.2 Lent 
  0.5 Lent 





3.2.8 DNA methylation simulation 
 We used the 200 null phenotypes described in 2.2.3–associated with gestational 
age and sex, but not DNA methylation–to evaluate type I error in each multi-tissue 
method. 
 Among methods with well controlled type I error, we evaluated power under 18 
different scenarios (Table 3.2). For each scenario we simulated 1000 phenotypes 
associated with methylation. We chose 3 different CpG sites with intra-individual 
correlations of 0.2, 0.5, and 0.8. We simulated four different effect sizes: no effect 
(partial R2=0), weak (partial R2=0.02), moderate (partial R2=0.03), and strong (partial 
R2=0.04). In half of our simulation scenarios, there was no effect in placenta, and in the 
other half, there was a weak association in placenta. In all scenarios, there was either a 
weak, moderate, or strong association in cord blood. We simulated Yi using the following 
equation: 
𝑌! = 𝛽!"# ⋅ 𝑆𝑒𝑥 + 𝛽!" ⋅ 𝑔𝑒𝑠𝑡𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑔𝑒 + 𝛽!" ⋅𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛!" 
+ 𝛽!" ⋅𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛_𝐹𝑃 + 𝑒! , 
where  𝛽!"# =
0.016
𝑉𝑎𝑟 𝑠𝑒𝑥  , 𝛽!" =
0.142
𝑉𝑎𝑟 𝑔𝑒𝑠𝑡𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑔𝑒   ,  
𝛽!"#$ !"##$ =
partial 𝑅!
𝑉𝑎𝑟 𝐶𝑜𝑟𝑑 𝑏𝑙𝑜𝑜𝑑 𝑚𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛  , 
   𝛽!"#$%&'# =
partial 𝑅!
𝑉𝑎𝑟 𝑃𝑙𝑎𝑐𝑒𝑛𝑡𝑎 𝑚𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛  , 




 It is important to note that in the presence of high correlation between tissues, a 
simulated association in cord blood will also result in an observed association in placenta. 
In the most extreme case, where both tissues are perfectly correlated, the strength of the 
observed association will be the same in both tissues regardless of which is simulated to 
have the “true” effect. 
Table 3.2 Power scenarios for multi-tissue analysis 
Scenario Cord blood partial R2 
Placenta 
partial R2 CpG site 
Intra-ID 
correlation 
1 0.02 0 cg21321039 0.2 
2 0.03 0 cg21321039 0.2 
3 0.04 0 cg21321039 0.2 
4 0.02 0.02 cg21321039 0.2 
5 0.03 0.02 cg21321039 0.2 
6 0.04 0.02 cg21321039 0.2 
7 0.02 0 cg03426840 0.5 
8 0.03 0 cg03426840 0.5 
9 0.04 0 cg03426840 0.5 
10 0.02 0.02 cg03426840 0.5 
11 0.03 0.02 cg03426840 0.5 
12 0.04 0.02 cg03426840 0.5 
13 0.02 0 cg25176297 0.8 
14 0.03 0 cg25176297 0.8 
15 0.04 0 cg25176297 0.8 
16 0.02 0.02 cg25176297 0.8 
17 0.03 0.02 cg25176297 0.8 
18 0.04 0.02 cg25176297 0.8 
 
3.3 Results  
3.3.1 Summary statistics simulation 
With independent studies, our numeric approximation gave very similar estimates 
to Chen et al.’s method. Figures 3.2-3.10 show a comparison of our numeric 




The correlation between estimates was 0.99 for 𝛽!, 𝑆𝐸 𝛽! ,𝛽!, and 𝑆𝐸 𝛽!  in all 9 
scenarios.  
Table 3.3 shows the bias and mean squared error (MSE) of the summary 
parameter estimates (𝛽! and 𝛽!) in all scenarios, and Table 3.4 shows the bias of the 
between-study covariance matrix estimate (𝑇) in all scenarios. As the proportion of 
variance in the first and second effects explained by heterogeneity increased, bias in both 
methods decreased. After introducing dependence between studies, the bias of our 





Figure 3.2 Comparison of random effects meta-analysis summary estimates when 
I21=0.2 and I22=0.2 
  
Comparison of estimates using Chen’s method of moments estimator and our numeric 
approximation across 1000 simulations, where 𝐼!! = 0.2, 𝐼!! = 0.2, and studies were 
independent. The Pearson correlation between estimates, r, is shown in the lower left 






Figure 3.3 Comparison of random effects meta-analysis summary estimates when 
I21=0.2 and I22=0.5 
 
Comparison of estimates using Chen’s method of moments estimator and our numeric 
approximation across 1000 simulations, where 𝐼!! = 0.2, 𝐼!! = 0.5, and studies were 
independent. The Pearson correlation between estimates, r, is shown in the lower left 






Figure 3.4 Comparison of random effects meta-analysis summary estimates when 
I21=0.2 and I22=0.8 
 
Comparison of estimates using Chen’s method of moments estimator and our numeric 
approximation across 1000 simulations, where 𝐼!! = 0.2, 𝐼!! = 0.8, and studies were 
independent. The Pearson correlation between estimates, r, is shown in the lower left 





Figure 3.5 Comparison of random effects meta-analysis summary estimates when 
I21=0.5 and I22=0.2 
 
Comparison of estimates using Chen’s method of moments estimator and our numeric 
approximation across 1000 simulations, where 𝐼!! = 0.5, 𝐼!! = 0.2, and studies were 
independent. The Pearson correlation between estimates, r, is shown in the lower left 





Figure 3.6 Comparison of random effects meta-analysis summary estimates when 
I21=0.5 and I22=0.5 
 
Comparison of estimates using Chen’s method of moments estimator and our numeric 
approximation across 1000 simulations, where 𝐼!! = 0.5, 𝐼!! = 0.5, and studies were 
independent. The Pearson correlation between estimates, r, is shown in the lower left 





Figure 3.7 Comparison of random effects meta-analysis summary estimates when 
I21=0.5 and I22=0.8 
 
Comparison of estimates using Chen’s method of moments estimator and our numeric 
approximation across 1000 simulations, where 𝐼!! = 0.2, 𝐼!! = 0.5, and studies were 
independent. The Pearson correlation between estimates, r, is shown in the lower left 






Figure 3.8 Comparison of random effects meta-analysis summary estimates when 
I21=0.8 and I22=0.2 
 
Comparison of estimates using Chen’s method of moments estimator and our numeric 
approximation across 1000 simulations, where 𝐼!! = 0.8, 𝐼!! = 0.2, and studies were 
independent. The Pearson correlation between estimates, r, is shown in the lower left 






Figure 3.9 Comparison of random effects meta-analysis summary estimates when 
I21=0.8 and I22=0.5 
 
Comparison of estimates using Chen’s method of moments estimator and our numeric 
approximation across 1000 simulations, where 𝐼!! = 0.8, 𝐼!! = 0.5, and studies were 
independent. The Pearson correlation between estimates, r, is shown in the lower left 






Figure 3.10 Comparison of random effects meta-analysis summary estimates when 
I21=0.8 and I22=0.8 
 
Comparison of estimates using Chen’s method of moments estimator and our numeric 
approximation across 1000 simulations, where 𝐼!! = 0.8, 𝐼!! = 0.8, and studies were 
independent. The Pearson correlation between estimates, r, is shown in the lower left 






Table 3.3 Bias and MSE of regression coefficients in summary statistics simulation 
𝑰𝟏𝟐 𝑰𝟐𝟐 Dependence Method 𝑩𝒊𝒂𝒔(𝜷𝟏) 𝑩𝒊𝒂𝒔(𝜷𝟐) 𝑴𝑺𝑬(𝜷𝟏) 𝑴𝑺𝑬(𝜷𝟐) 
0.2 0.2 0.0 Chen 0.0101 -0.0003 0.0292 0.0308 
  0.0 Lent 0.0097 -0.0001 0.0295 0.0307 
  0.2 Lent 0.0079 -0.0027 0.0651 0.0608 
  0.5 Lent -0.0203 0.0112 0.0608 0.0635 
  0.8 Lent 0.0065 -0.0013 0.0501 0.0544 
0.2 0.5 0.0 Chen -0.0046 -0.0007 0.0306 0.0514 
  0.0 Lent -0.0046 -0.0008 0.0306 0.0515 
  0.2 Lent -0.0121 -0.0031 0.0591 0.0851 
  0.5 Lent 0.0024 -0.0113 0.0629 0.0976 
  0.8 Lent -0.0179 -0.0030 0.0590 0.0820 
0.2 0.8 0.0 Chen 0.0006 0.0243 0.0329 0.1088 
  0.0 Lent 0.0009 0.0245 0.0329 0.1087 
  0.2 Lent -0.0200 0.0010 0.0591 0.1718 
  0.5 Lent 0.0043 -0.0210 0.0633 0.1543 
  0.8 Lent 0.0058 -0.0126 0.0542 0.1504 
0.5 0.2 0.0 Chen 0.0038 0.0102 0.0488 0.0346 
  0.0 Lent 0.0038 0.0103 0.0486 0.0345 
  0.2 Lent 0.0151 -0.0183 0.0748 0.0624 
  0.5 Lent 0.0077 -0.0080 0.0841 0.0578 
  0.8 Lent -0.0083 -0.0101 0.0818 0.0574 
0.5 0.5 0.0 Chen 0.0025 0.0095 0.0504 0.0527 
  0.0 Lent 0.0023 0.0096 0.0504 0.0529 
  0.2 Lent -0.0058 -0.0115 0.0980 0.0885 
  0.5 Lent -0.0020 -0.0163 0.0901 0.0852 
  0.8 Lent -0.0064 0.0087 0.0868 0.0878 
0.5 0.8 0.0 Chen -0.0017 0.0132 0.0558 0.1070 
  0.0 Lent -0.0021 0.0131 0.0554 0.1070 
  0.2 Lent -0.0176 -0.0143 0.0895 0.1609 
  0.5 Lent 0.0017 -0.0022 0.0847 0.1647 
  0.8 Lent 0.0045 0.0068 0.0929 0.1639 
0.8 0.2 0.0 Chen -0.0053 -0.0118 0.0976 0.0341 
  0.0 Lent -0.0051 -0.0116 0.0977 0.0344 
  0.2 Lent 0.0004 -0.0051 0.1624 0.0610 
  0.5 Lent 0.0040 -0.0036 0.1519 0.0665 
  0.8 Lent -0.0135 0.0022 0.1652 0.0614 
0.8 0.5 0.0 Chen 0.0001 -0.0037 0.1073 0.0524 
  0.0 Lent -0.0004 -0.0037 0.1076 0.0527 
  0.2 Lent -0.0108 -0.0075 0.1559 0.0884 
  0.5 Lent 0.0072 0.0018 0.1753 0.0901 
  0.8 Lent 0.0224 -0.0070 0.1535 0.0909 
0.8 0.8 0.0 Chen -0.0006 -0.0068 0.1165 0.1166 
  0.0 Lent -0.0006 -0.0069 0.1167 0.1168 
  0.2 Lent 0.0037 0.0115 0.1867 0.1701 
  0.5 Lent 0.0166 0.0045 0.1832 0.1676 




Table 3.4 Bias of random effect estimates in summary statistics simulation  
𝑰𝟏𝟐 𝑰𝟐𝟐 Dependence Method 𝑩𝒊𝒂𝒔(𝑻𝟏𝟏) 𝑩𝒊𝒂𝒔(𝑻𝟏𝟐) 𝑩𝒊𝒂𝒔(𝑻𝟐𝟐) 
0.2 0.2 0.0 Chen 0.0521 0.0033 0.0536 
  0.0 Lent 0.0554 0.0069 0.0572 
  0.2 Lent 0.0469 0.0082 0.0465 
  0.5 Lent 0.0421 0.0122 0.0463 
  0.8 Lent 0.0463 0.0074 0.0411 
0.2 0.5 0.0 Chen 0.0522 0.0051 0.0257 
  0.0 Lent 0.0547 0.0096 0.0300 
  0.2 Lent 0.0517 0.0066 0.0334 
  0.5 Lent 0.0513 0.0046 0.0294 
  0.8 Lent 0.0551 0.0066 0.0376 
0.2 0.8 0.0 Chen 0.0497 -0.0019 -0.0050 
  0.0 Lent 0.0514 0.0032 -0.0015 
  0.2 Lent 0.0426 -0.0023 -0.0024 
  0.5 Lent 0.0423 -0.0032 0.0099 
  0.8 Lent 0.0450 0.0085 -0.0083 
0.5 0.2 0.0 Chen 0.0342 0.0025 0.0521 
  0.0 Lent 0.0374 0.0069 0.0551 
  0.2 Lent 0.0255 0.0033 0.0451 
  0.5 Lent 0.0284 0.0025 0.0477 
  0.8 Lent 0.0331 0.0013 0.0413 
0.5 0.5 0.0 Chen 0.0346 -0.0002 0.0349 
  0.0 Lent 0.0376 0.0037 0.0380 
  0.2 Lent 0.0282 0.0096 0.0253 
  0.5 Lent 0.0274 0.0001 0.0266 
  0.8 Lent 0.0420 0.0072 0.0264 
0.5 0.8 0.0 Chen 0.0292 0.0024 0.0153 
  0.0 Lent 0.0300 0.0070 0.0192 
  0.2 Lent 0.0356 0.0077 0.0383 
  0.5 Lent 0.0266 -0.0025 0.0087 
  0.8 Lent 0.0198 -0.0073 0.0109 
0.8 0.2 0.0 Chen 0.0018 -0.0097 0.0492 
  0.0 Lent 0.0057 -0.0029 0.0507 
  0.2 Lent 0.0120 0.0064 0.0419 
  0.5 Lent 0.0209 0.0061 0.0471 
  0.8 Lent 0.0022 -0.0043 0.0414 
0.8 0.5 0.0 Chen 0.0298 -0.0027 0.0333 
  0.0 Lent 0.0323 -0.0006 0.0357 
  0.2 Lent 0.0230 -0.0074 0.0311 
  0.5 Lent -0.0078 0.0063 0.0299 
  0.8 Lent -0.0014 -0.0165 0.0257 
0.8 0.8 0.0 Chen 0.0139 0.0047 0.0505 
  0.0 Lent 0.0148 0.0057 0.0529 
  0.2 Lent 0.0055 0.0039 -0.0078 
  0.5 Lent 0.0283 0.0051 -0.0128 




3.3.2 DNA methylation simulation type I error 
 GCB proved to be too computationally intensive for a simulation study. After 
analyzing 10,000 CpG sites, we determined that one simulation across the genome would 
take 28 days using 20 cores. Therefore, we restricted our type I error analysis to LME, 
FEL, FEB, and REB. Table 3.5 shows the ratio of the observed to expected type I error 
rates for these 4 methods at several different significance levels, α.  
 The tissue-specific EWAS and LME had well controlled type I error, but all other 
methods had inflated error rates. In particular, the precision parameters from beta 
regression models in both tissues had very high error rates, with observed error rates over 
100 times the expected error rate at α =1×10-6. Therefore, we evaluated power only in the 





Table 3.5 Ratio of mean observed type I error rates to expected type I error rates 
for multi-tissue methods 
Method α 5×10-2 1×10-2 1×10-3 1×10-4 1×10-5 1×10-6 
Linear model EWAS       
Placenta 1.00 1.00 1.16 1.50 1.56 1.47 
Cord blood 1.00 0.97 0.88 0.74 0.64 0.58 
LME  0.98 0.95 0.90 0.79 0.61 0.45 
FEL 1.50 2.07 3.75 8.34 22.87 75.84 
Beta regression        
Placenta mean 1.22 1.41 1.96 3.01 4.57 7.82 
Placenta precision 1.79 2.78 6.02 15.49 47.37 167.87 
Cord blood mean 1.16 1.26 1.36 1.45 1.66 2.17 
Cord blood precision 1.53 2.14 4.05 9.93 32.03 127.90 
FEB 1.56 2.21 4.27 10.30 31.76 126.89 
REB 0.71 0.81 1.24 2.49 6.69 24.61 
Ratio of mean observed type I error rates to expected type I error rates for all multi-tissue 
methods at various significance levels, α. Mean observed error rates were calculated 
across 100 simulations for each method. Values greater than 1 indicate inflated type I 
error. 
 
3.3.3 DNA methylation simulation power 
 We defined power as the proportion of simulations where the simulated CpG site 
was detected at the α=0.05 level, after adjusting for multiple testing using a Bonferroni 
correction. For the tissue-specific EWAS models, the Bonferroni significance level was 
0.05/(790,979×2)=3.2×10-8, and for the LME model, the Bonferroni significance level 
was 0.05/790,979=6.3×10-8. We calculated the power to detect an association in each 
tissue-specific EWAS separately as well as the power to detect an association in either 




For a CpG site with weak intra-individual correlation, modeling both tissues 
jointly decreased power compared to tissue-specific EWAS when only one tissue was 
associated and increased power when both tissues were associated (Figure 3.11). Notably, 
when there was a strong association in cord blood and weak association in placenta, 
modeling both tissues in the LME model greatly increased power compared to the cord 
blood EWAS. In this case, the power of LME was greater than the power of both EWAS 
models combined.  
For a CpG site with moderate intra-individual correlation, we saw the same trend 
(Figure 3.12). However, the difference in power between the cord blood EWAS and LME 
when there was a strong association in cord blood and weak association in placenta was 
not as dramatic when the CpG site had moderate intra-individual correlation. This is 
expected, because as the intra-individual correlation increases, we observe more of the 
simulated placenta association in the cord blood EWAS. In other words, adding placenta 
to the model doesn’t contribute as much independent evidence of association when the 
correlation between tissues is higher. 
For a CpG site with strong intra-individual correlation, modeling both tissues 
jointly decreased power compared to the tissue-specific EWAS when only one tissue was 
strongly associated and the other tissue had no association (Figure 3.13). When both 
tissues were associated, power was highest for the LME model, although the difference 
was minor. Again, this is expected, because with high intra-individual correlation, adding 
a second tissue to the model adds very little new information. Because the tissues are so 




All methods had low (<25%) power to detect a strong association in cord blood only, but 
almost 100% power to detect both a strong association in cord blood and weak 
association in placenta. No methods were able to detect a weak or moderate association 






Figure 3.11 Power to detect association at cg21321039 in multi-tissue analysis 
 
Simulated power to detect an association at cg25176297, where the Pearson correlation 
between tissues is 0.2. The CpG site was simulated to have a weak (row 1, partial 
R2=0.02), moderate (row 2, partial R2=0.03), or strong (row 3, partial R2=0.04) 
association with the phenotype in cord blood, and either no association (column 1, partial 





Figure 3.12 Power to detect association at cg03426840 in multi-tissue analysis 
 
Simulated power to detect an association at cg03426840, where the Pearson correlation 
between tissues is 0.5. The CpG site was simulated to have a weak (row 1, partial 
R2=0.02), moderate (row 2, partial R2=0.03), or strong (row 3, partial R2=0.04) 
association with the phenotype in cord blood, and either no association (column 1, partial 





Figure 3.13 Power to detect association at cg25176297 in multi-tissue analysis 
 
Simulated power to detect an association at cg21321039, where the Pearson correlation 
between tissues is 0.8. The CpG site was simulated to have a weak (row 1, partial 
R2=0.02), moderate (row 2, partial R2=0.03), or strong (row 3, partial R2=0.04) 
association with the phenotype in cord blood, and either no association (column 1, partial 






 Of the methods with well controlled type I error in multi-tissues analyses–cord 
blood EWAS, placenta EWAS, and LME–we showed that LME was the most powerful 
when both tissues were associated and the tissue-specific EWAS were most powerful 
when only one tissue was associated. This is what we expected, as adding an 
unassociated tissue to a joint model just contributes more noise to the model. 
We also showed that our novel method for meta-analyzing multiple parameters 
from multiple studies has comparable performance to Chen et al.’s meta-analysis method 
when studies are independent. Furthermore, our method can be applied to correlated 
studies, making it appropriate for meta-analyzing multiple parameters from multiple 
DNA methylation tissue models. 
 Unfortunately, because the beta regression model precision parameters had 
inflated type I error, the type I error of our meta-analysis method was also inflated. 
However, this method may be useful for meta-analyzing multivariate exposures or 
outcomes in multiple tissues. For instance, studies on gestational diabetes mellitus 
(GDM) have found associations between both cord blood and placenta DNA methylation 
and GDM69-71. GDM is diagnosed using a 2-hour 75g oral glucose test, where glucose is 
measured 3 times in each patient: at baseline (fasting), 1 hour after glucose exposure, and 
2 hours after glucose exposure72. If any of these 3 glucose measurements is abnormally 
high, the patient is diagnosed with GDM72. Our meta-analysis would be useful for meta-




methylation in both cord blood and placenta.  In the future, we plan to evaluate our meta-




CHAPTER 4: Gene set analysis 
4.1 Introduction 
 There are many flexible gene set analysis tools available, which have been 
applied to results from GWAS, gene expression microarray, RNA-sequencing, and DNA 
methylation studies35,36,73-78. These methods take a list of associated genes, and 
sometimes gene summary statistics, as input, and test whether known, pre-defined gene 
sets are enriched for associated genes.  Often, the underlying assumption of these 
methods is that the probability of a false positive association is the same for all genes{37. 
This is not appropriate for some association statistics, such as the minimum P-value or 
the maximum test statistic, because genes with a larger number of measured SNPs or 
CpG sites are more likely to be implicated by chance if multiple testing is not properly 
taken into consideration{37. 
Young et al. 79 developed an approach to account for bias toward particular genes 
in RNA-sequencing studies, ‘goseq’, and both Geeleher et al. 37 and Phipson et al. 80 
extended this approach for DNA methylation studies. Both of these extensions, while 
appropriate for methylation data, require a list of associated genes as input. This is useful 
for detecting patterns in a long list of associated genes from an EWAS, but not useful for 
aggregating weakly or moderately associated sites in the same pathway that do not 
achieve statistical significance after correcting for multiple testing. 
We consider MAGENTA, a gene set analysis method developed to aggregate 
weak and moderate single-nucleotide polymorphism (SNP) associations in known gene 




computes enrichment using individual p-values for all genetic variants in a gene, and 
corrects for genetic confounders that make a false positive result more likely for certain 
genes when using the maximum test statistic over all SNPs as the measure of association 
between a particular phenotype and a gene. MAGENTA has not been rigorously 
evaluated for analyzing methylation data (using EWAS summary statistics as input 
instead of GWAS summary statistics). Furthermore, an underlying assumption of 
MAGENTA is that there is single measure of association for each SNP34. This 
assumption is violated when analyzing CpG sites from tissue-specific EWAS association 
results from k tissues, because we have k association statistics per site. 
 In this chapter, we evaluate the performance of MAGENTA for performing gene 
set enrichment analysis using summary statistics from one or two tissue-specific EWAS. 
For the single-tissue gene set enrichment analysis, we use one z-statistic per CpG site as 
input, and for the multi-tissue gene set enrichment analysis, we use two z-statistics per 
CpG site as input (one from each tissue-specific EWAS). We also propose an extension 
to the MAGENTA approach, controlling for common epigenetic confounders rather than 
genetic confounders, and compare its performance to the original MAGENTA approach 
in a simulation study and real data analysis.   
4.2 Methods 
4.2.1 Original MAGENTA method 
 In order to detect gene sets with a large number of associations that may not reach 
genome-wide significance, MAGENTA employs a competitive approach, comparing the 




genes not in the pathway. Each gene is assigned a score, and each gene set is tested to 
determine if it contains more genes above a certain score percentile than expected by 
chance. The algorithm is as follows: 
1. Map individual SNPs to genes 
By default, all SNPs between 110,000 base pairs upstream and 40,000 bp 
downstream of a gene’s boundaries are mapped to that gene, but the user may 
change these boundaries. The default boundaries around a gene were chosen 
specifically for SNPs based on the average observed distance between a gene and 
a SNP associated with the expression level of that gene34. One SNP may be 
mapped to multiple genes.  
2. Calculate gene scores 
Each gene is assigned an unadjusted gene score, equal to the minimum p-value of 
all SNPs mapped to that gene 
3. Correct gene scores for confounding factors 
Many genetic confounders, such as gene size, make it more likely that some genes 
will have a more significant gene score than others. To account for this, stepwise 
linear regression is used to adjust for up to four confounders: gene size (GS), 
number of genetic variants (GV), number of independent genetic variants (IGV), 
and number of recombination hotspots (RH). The full model is given by 
𝐸[𝑧!"#"] = 𝛽!𝐺𝑆 + 𝛽!𝐺𝑉 + 𝛽!𝐼𝐺𝑉 + 𝛽!𝑅𝐻 
where 𝑧!"#" is the inverse-normal transformation of the minimum p-value of all 




from the model if p>0.1. The adjusted gene score, 𝑧!"#, is given by the residuals 
of the final stepwise linear regression model.  
4. Filter genes and gene sets 
If multiple genes in the same gene set are assigned to the same best SNP, only the 
gene with the highest adjusted score, 𝑧!"#, is retained in the permutation test in 
step 5. Gene sets with fewer than 10 genes after filtering are not evaluated in step 
5. 
5. Calculate gene set enrichment p-values 
A leading edge fraction, the proportion of genes with adjusted scores in the top 
5% of all adjusted gene scores, is calculated for each gene set. Users may choose 
any percentile cutoff, but by default MAGENTA reports results for both 5% and 
25% cutoffs. The authors recommend using the 5% cutoff as it had the highest 
power to detect associations in their simulation study. After calculating the 
leading edge fraction for each gene set, 10,000 sets of adjusted gene scores of the 
same size as the gene set of interest are randomly sampled. A leading edge 
fraction is calculated for each of these 10,000 sets of randomly sampled adjusted 
gene scores. The enrichment p-value for the gene set is the proportion of the 
10,000 random leading edge fractions at least as large as the observed leading 
edge fraction.  
Although MAGENTA was developed for GWAS summary statistics (one p-value 
per SNP), we use EWAS summary statistics as input in our implementation. For the 




analysis, we provide two p-values per CpG site (one per tissue). Therefore, in the multi-
tissue analysis, twice as many CpG site p-values are mapped to a gene compared to the 
single-tissue analysis in step 1 of the algorithm, and gene scores are calculated as the 
minimum CpG site p-value in either tissue in step 2 of the algorithm. Rather than 
extending each gene’s boundaries by the default values (110,000 bp upstream and 40,000 
downstream) around a gene when mapping CpG sites to genes, we add only 10,000 bp 
upstream and 10,000 bp downstream. 
4.2.2 Extension to MAGENTA for DNA methylation studies 
 Two of the genetic confounders used in MAGENTA, the number of independent 
SNPs and number of recombination hotspots, are relevant to GWAS data but not 
necessarily methylation data. We propose using 3 epigenetic confounders for analyzing 
association results from a single tissue: gene size in kilobases (kb), number of CpG sites 
per kb, and CpG site variance averaged over all CpG sites within a gene. We propose 
controlling for the average CpG site variance because many CpG sites do not vary much 
across individuals and thus are uninformative81. The average variance across all CpG 
sites in a gene gives a measure of the number of informative CpG sites in a gene. When 
analyzing association results from two tissues, we consider an additional potential 
confounder, the average intra-individual correlation across all CpG sites in a gene. For 
more than two tissues, we could use the condition number described in Chapter 2, 𝜅, as a 
potential confounder instead of the correlation. We evaluated several transformations of 
these potential confounders. In many cases, the homoscedasticity assumption was 




meet the assumption of homoscedasticity, we take the log transformation of both the gene 
size and average CpG site variance. Figure 4.2 shows the distribution of the residuals for 
one multi-tissue simulation using these transformations. 
 As described above, the original software uses a permutation test to evaluate 
whether each pathway has more genes with adjusted scores in the top 5% than expected 
by chance. This permutation test is computationally intense, and, assuming the gene 
scores are independent, should be equivalent to a binomial test with the null hypothesis 
that the probability of being in the top 5% is 0.05. We know that gene scores are not 
independent, because nearby genes are correlated with one another, but filtering out 
genes mapped to the same top SNP (or CpG site) may be sufficient to remove highly 
correlated genes. Therefore, we evaluate both a permutation test and binomial test in our 
simulations. 
There are a few other minor differences between the original MAGENTA 
algorithm and our implementation. In the original MAGENTA algorithm, genes in 
different pathways mapped to the same top SNP are all retained, but genes in the same 
pathway mapped to the same SNP are filtered (described in step 4 above). We perform 
gene filtering separately for each pathway test and filter genes mapped to the same SNP 
regardless of whether they share a pathway. If none of the genes in question belong to the 
pathway being tested, we randomly select one gene to retain in the analysis. If any of the 
genes in question are in the pathway being tested, we randomly select one of the genes 
belonging to this pathway to retain in the analysis. This filtering strategy is more 




employ a more stringent filtering strategy in order to reduce correlation between 
neighboring genes in the permutation test. In order to preserve as many genes as possible, 
we reduce the boundaries around the gene in the mapping stage. While the original 
MAGENTA algorithm maps all SNPs between 110,000 base pairs upstream and 40,000 
bp downstream of a gene’s boundaries to the gene, we only extend 10,000 base pairs 
upstream and 10,000 base pairs downstream of the gene’s boundaries. Finally, we add or 
remove variables based on improvement in the model Akaike information criterion (AIC) 
rather than using p-value thresholds in the step-wise variable selection. 
4.2.3 Simulation study design 
  We used a multivariate normal distribution assumption for the EWAS summary 
statistics, described in Section 2.2.2, to simulate tissue-specific summary statistics that 
preserve the correlation structure observed in our study cohort methylation data. Previous 
evidence has shown that the correlation between neighboring CpG sites plateaus after 
about 5000 bp82. We partitioned the genome into blocks, where any two CpG sites within 
5000 bp were in the same block. Within each block, we simulated z-scores from a 
multivariate normal distribution, where the covariance matrix was estimated by the 
observed correlation between methylation measurements. Because we have two tissues in 
our sample, there were twice as many methylation measurements as CpG sites. 
 We evaluated MAGENTA and our extension by conducting a simulation study of 
Kyoto Encyclopedia of Genes and Genomes (KEGG) gene pathways83. In the type I error 
simulation, the mean of the multivariate normal distribution was zero for every CpG site, 




original MAGENTA paper, the authors drew z-scores from a chi-square distribution with 
a non-centrality parameter of 10 for associated variants in order to evaluate power. This 
effect size corresponds to 1% power in a single-variant GWAS analysis using the 
genome-wide significance threshold of 5×10!!. We simulated an equivalent effect size 
using the multivariate normal distribution, randomly selecting 1 CpG site per associated 
gene to have a z-score mean of 10. In each power simulation, the randomly selected 
associated genes were in the KEGG GNRH signaling pathway, which contains 101 
genes. We considered several power scenarios, varying the number of genes and number 
of tissues associated within the KEGG GNRH signaling pathway (Table 4.1). We 
performed 100 type I error simulations and 100 power simulations per scenario. 
 For both MAGENTA and our extension, we performed a gene set enrichment 






Table 4.1 Power scenarios for gene set analysis 
# of genes 
associated 
% of genes 
associated 
# of genes associated 
in cord blood 
# of genes associated 
in placenta 
5 5.0% 5 0 
5 5.0% 3 2 
5 5.0% 2 3 
5 5.0% 0 5 
10 9.9% 10 0 
10 9.9% 5 5 
10 9.9% 0 10 
20 19.8% 20 0 
20 19.8% 10 10 
20 19.8% 0 20 
Each associated gene has 1 associated CpG site with an expected z-score of 3.16. 
Associated genes are randomly selected from the KEGG GNRH signaling pathway in 





Figure 4.1 Residuals from possible stepwise linear model with heteroscedasticity 
 
Plot of residuals against both fitted values (blue) and individual covariate levels (grey) 
for the stepwise linear regression model from one multi-tissue simulation. Of the 4 
confounders considered (log-transformed gene size, log-transformed number of CpG sites 
per kb, mean CpG site variance, and mean intra-individual correlation), 3 were included 
in the final stepwise linear regression model, chosen to maximize AIC. The linear 
regression assumption of homoscedasticity is violated, with larger variance in residuals 






Figure 4.2 Residuals from final stepwise linear regression model for one simulation  
 
Plot of residuals against both fitted values (blue) and individual covariate levels (grey) 
for the stepwise linear regression model from one multi-tissue simulation. Of the 4 
confounders considered (log-transformed gene size, number of CpG sites per kb, log-
transformed mean CpG site variance, and mean intra-individual correlation), 3 were 
included in the final stepwise linear regression model, chosen to maximize AIC. The 





4.2.4 Real data analysis 
 We applied all methods to an analysis of birth weight in Gen3G. Table 2.2 shows 
some summary information about the Gen3G sample, including information on birth 
weight, sex, and gestational age. We tested whether any of the 186 KEGG gene sets were 
enriched for association with birth weight. In each tissue separately, we modeled birth 
weight as a function of methylation M-values, gestational age, and sex. Because the 
KEGG database has been updated since the release of MAGENTA, our analysis contains 
a greater number of gene sets for the MAGENTA extension. Because the number of 
genes retained in the analysis depends on how many genes are mapped to the same top 
CpG site (i.e. how many genes are filtered out), and gene sets with fewer than 10 genes 
are not evaluated, the number of gene sets evaluated varies slightly depending on the 
data. After filtering genes and gene sets, there were 140 KEGG pathways remaining in 
the extended MAGENTA analysis of both tissues, 138 in cord blood, and 141 in placenta.  
For the original MAGENTA method, there were 136 gene sets in each analysis. 
4.3 Results 
Simulation study type I error 
 In general, type I error was well controlled for both methods using one or two 
tissues at the nominal α=0.05 level (Table 4.2). The extended method was conservative at 
the α=0.05 level, with observed type I error rates between 64-98% of the expected type I 
error rate. At the α=0.01 level, the original MAGENTA algorithm had slightly inflated 




Table 4.2 Ratio of observed to expected type I error rates in gene set analysis 
  α 
Method Tissue(s) 0.05 0.01 
MAGENTA (original algorithm) Cord blood 1.04 1.15 
Placenta 1.11 1.31 
Both tissues 1.14 1.29 
MAGENTA extension, permutation test  Cord blood 0.98 1.00 
Placenta 0.80 0.99 
 Both tissues 0.64 0.98 
MAGENTA extension, binomial test Cord blood 0.93 0.96 
Placenta 0.80 0.93 
 Both tissues 0.74 1.02 
Values greater than 1 indicate inflated type I error. 
Simulation study power 
Figures 4.3 and 4.4 show the power (and 95% confidence interval) to detect the 
simulated association in the KEGG GNRH signaling pathway under each power scenario 
described in Table 4.1 for both the original MAGENTA algorithm and our extension, 
applied to summary statistics from cord blood only, placenta only, and both tissues. 
When only 5 out of the 101 genes in the KEGG GNRH signaling pathway were 
simulated to have one associated CpG site, power was near 0 across all methods. This 
supports the findings in the original simulation study of MAGENTA by Segrè et al that 
power to detect a pathway where 5 out of 100 genes were associated with the phenotype 
was extremely low34. 
When 10 out of the 101 genes were associated, power improved for both methods, 
but the original MAGENTA algorithm had as much or higher power than our extension 
in the multi-tissue and cord blood analysis, while our extension had as much or higher 




in cord blood and 5 of the associations were in placenta, power was higher in the multi-
tissue analyses than the tissue-specific analyses, and when all 10 associations were in one 
tissue, power was higher in the tissue-specific analysis. However, power was less than 
10% for all methods, so more than 100 simulations are needed to properly evaluate any 
potential difference between methods. 
Finally, when 20 of the KEGG GNRH signaling pathway genes were associated, 
power improved dramatically (Figure 4.4). As expected, the cord blood analysis was 
most powerful for both methods when all 20 associations were in cord blood, the placenta 
analysis most powerful when all 20 associations were in placenta, and the multi-tissue 
analysis most powerful when there were 10 associated genes in each tissue. The original 
MAGENTA algorithm was at least as powerful as our method in all scenarios. 
Overall, our method was less powerful than the original MAGENTA algorithm in 
most scenarios. Within our method, the permutation test and binomial test had near 








Figure 4.3 Power to detect pathway with 10 out of 101 genes associated   
 
Power (and 95% confidence interval) to detect the simulated pathway association in the 
KEGG GNRH signaling pathway, when 10 out of 101 genes contained one CpG site with 







Figure 4.4 Power to detect pathway with 20 out of 101 genes associated   
 
Power (and 95% confidence interval) to detect the simulated pathway association in the 
KEGG GNRH signaling pathway, when 20 out of 101 genes contained one CpG site with 





Real data analysis 
There were 451 infants in the cord blood analysis of birth weight, 448 infants in 
the placenta analysis, and 444 infants in both analyses. There was 1 significantly enriched 
KEGG pathway (Olfactory transduction) in both tissues and in just placenta after 
adjusting for multiple testing with a Bonferroni correction using the extended 
MAGENTA approach. Using the original MAGENTA algorithm, there was 1 pathway 
significantly enriched in cord blood (Regulation of actin cytoskeleton), 1 in placenta 
(Glyoxylate and dicarbonate metabolism), and 1 in both tissues (Natural killer cell 
mediated cytotoxicity). The top 5 pathways for each method and tissue are shown in 
Tables 4.3-4.5. There was no overlap in the top 5 pathways identified by the original 
MAGENTA algorithm and our extension.  
The results in the multi-tissue analysis using the original MAGENTA algorithm 
appeared to be largely driven by an association in cord blood. For the natural killer cell 
mediated cytotoxicity, 13 out of 97 genes were in the top 5% of all adjusted gene scores 
in cord blood only (Table 4.5), while 15 out of 97 genes were in the top 5% of all 
adjusted gene scores using information from both tissues (Table 4.3). In both the cord 
blood and multi-tissue analysis, 6 out of 32 genes in the dorsoventral axis formation 
pathway had genes in the top 5% of all adjusted gene scores, suggesting that adding 
placenta to the analysis did not contribute any new information. There was no overlap in 
the top 5 pathways identified in the multi-tissue analysis and placenta analysis for the 




For our extension to the MAGENTA algorithm, most of the top 5 results in the 
multi-tissue analysis appeared to be driven by only one tissue. The only significant 
associated pathway, olfactory transduction, was significantly enriched in placenta, but not 
cord blood. 
 
Table 4.3 Top 5 gene sets in both tissues for each method 
Method KEGG pathway # of genes in pathway 
# of genes 
with scores 
in top 5% 
P-value 
MAGENTA Natural killer cell mediated 
cytotoxicity 
97 15 0.0001 
Regulation of actin 
cytoskeleton 
181 18 0.0031 
Dorsoventral axis formation 32 6 0.0041 
Ethylbenzene degradation 15 4 0.0050 
FC epsilon RI signaling 
pathway 





Olfactory transduction 328 34 0.0001 
Leishmania infection 48 7 0.0075 
Endocytosis 129 13 0.0124 
Nod-like receptor signaling 
pathway 
46 6 0.0258 
B cell receptor signaling 
pathway 




Olfactory transduction 328 34 0.00007 
Leishmania infection 48 7 0.0009 
Endocytosis 129 13 0.0141 
Nod-like receptor signaling 
pathway 
46 6 0.0263 
B cell receptor signaling 
pathway 






Table 4.4 Top 5 gene sets in cord blood for each method 
Method KEGG pathway # of genes in pathway 
# of genes 
with scores 
in top 5% 
P-value 
MAGENTA Regulation of actin 
cytoskeleton 
181 23 0.0002 
Natural killer cell mediated 
cytotoxicity 
97 13 0.0015 
Glutamate metabolism 30 6 0.0035 
Longterm potentiation 65 9 0.0048 





MAPK signaling pathway 197 20 0.0016 
Leishmania infection 48 8 0.0019 
Nod-like receptor signaling 
pathway 
46 8 0.0024 
Cytokine receptor interaction 189 19 0.0030 
 
T cell receptor signaling 
pathway 




Nod-like receptor signaling 
pathway 
46 8 0.0018 
Leishmania infection 48 8 0.0024 
MAPK signaling pathway 197 20 0.0027 
Cytokine receptor interaction 189 19 0.0039 
T cell receptor signaling 
pathway 







Table 4.5 Top 5 gene sets in placenta for each method 
Method KEGG pathway # of genes in pathway 
# of genes 
with scores 
in top 5% 
P-value 
MAGENTA Glyoxylate and dicarbonate 
metabolism 
13 5 0.0003 
Custom calcium channel 27 6 0.0006 
Citrate cycle TCA cycle 27 5 0.0093 
Nicotinate and nicotinamide 
metabolism 
64 7 0.0229 









57 6 0.0606 
Glyoxylate and dicarboxylate 
metabolism 
11 2 0.1049 
Cardiac muscle contraction 56 5 0.1395 




Olfactory transduction 327 53 6x10-14 
Focal adhesion 147 2 0.0368 




57 6 0.0646 
MAPK signaling pathway 195 4 0.0951 
 
4.4 Discussion 
We proposed two extensions to the original MAGENTA software, which adjusts 
maximum gene association statistics from GWAS for common genetic confounders and 
uses a permutation test in order to identify gene pathways with higher adjusted gene 
scores than expected by chance. We proposed adjusting for epigenetic confounders rather 
than genetic confounders, and employed both a permutation test and binomial test to 
evaluate whether gene pathways had higher adjusted scores than expected by chance. 




below the expected error rate. In the future, we plan to evaluate alternate methods of 
correcting gene scores. In the original MAGENTA algorithm, the authors provide an 
option to correct minimum gene p-values using a Sidak correction, assuming the effective 
number of variants is about half of the number of variants34. This correction performed 
just as well, if not better than, the stepwise linear regression correction. We plan to 
evaluate this correction in the context of DNA methylation data and estimate an 
approximate effective number of CpG sites in the EPIC array. 
In the real data analysis, there was no overlap in the top 5 pathways identified by 
either method and previously published pathways related to birth weight12,84. Our 
extension identified 1 pathway enriched for associations in both tissues and in placenta 
alone. The original MAGENTA algorithm identified 1 enriched pathway in both tissues, 
cord blood alone, and placenta alone, but we found no prior evidence of birth weight 
association in these pathways in the literature. Further investigation of the genes in these 
pathways is warranted to better determine whether these results are likely to be true 
associations or false positives. We plan to evaluate in the type I error simulations whether 
either of these methods are biased toward the pathways identified in the real data 
analysis. 
Our method appeared to be less powerful than the original MAGENTA algorithm. 
This could be due to the difference in the number of genes included in each pathway after 
filtering out overlapping genes in the same pathway. We plan to further investigate the 




CHAPTER 5: Conclusions and future work 
 There is still much progress to be made in analysis of DNA methylation data. 
There is evidence that single-tissue EWAS have low power, but there are no clear best 
practices for how to analyze multiple tissues, CpG sites, or gene pathways. We evaluated 
existing methods and proposed new methods to incorporate information from multiple 
tissues and sites.  
 In Chapter 2, we proposed a novel method, DMAnnot, to detect DMRs. Our 
method had higher power than EWAS and DMRcate to detect several independent weak 
or moderate associations in a region. In addition, we showed that comb-p, which had not 
been previously evaluated in a simulation study, had greatly inflated type I error, 
indicating that it may not be appropriate for analyzing EWAS results. One advantage to 
our method is that we can consider non-continuous segments of the genome. We plan to 
leverage this by analyzing DMRs defined by more complex annotations, such as those 
from the 3D Genome Browser55, in the future.  
 In Chapter 3, we proposed a novel meta-analysis method for analyzing multiple 
parameters from multiple correlated studies. We developed this method in order to meta-
analyze results from tissue-specific beta regression models. These models proved not to 
be appropriate for DNA methylation data because of inflated type I error in the precision 
parameters, which has been previously discussed85. Our method had inflated type I error 
due to the inflated type I error of the beta regression models. However, we showed in an 
additional simulation study of summary statistics that it had similar performance with 




to apply our method to meta-analyze multiple phenotypes estimated from linear models 
in multiple tissues. In particular, we plan to investigate the association between all three 
glucose measurements from a 75g oral glucose tolerance test (the diagnostic criteria for 
GDM) and methylation in both tissues in Gen3G. For multi-tissue analysis of a single 
phenotype, we suggest a standard LME model, which was the only multi-tissue method 
with well-controlled type I error. 
 In Chapter 4, we proposed an extension to the gene set analysis software 
MAGENTA, using epigenetic information to account for bias toward particular genes 
rather than genetic information. Our method had lower power than the original method, 
but better controlled type I error. In the future, we plan to investigate alternate methods of 
correcting for bias, including calculating an effective number of CpG sites in the Illumina 
arrays.  
 Each of the methods we propose is flexible and can be applied to future 
generations of methylation arrays, or whole-genome methylation bisulfate sequencing if 
available. We anticipate that these methods will increase power to detect biologically 
meaningful DNA methylation associations in individual cohorts with limited sample sizes 










 be the vector of 









, where 𝑏! is the 𝑝×1 vector of effect size estimates from study j. 
Model: 
 
𝑏!"×! =𝑊!"×!𝛽!×! + 𝑒!"×!,  where  𝑒~𝑀𝑉𝑁 0!"×!,𝛴!"×!"  
Per Becker and Wu (2008), the fixed effects estimate of 𝛽 for this model is given by66 
𝛽! = 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝑏, where 𝐶𝑜𝑣 𝛽! = 𝑊!𝛴!!𝑊 !! 
If we add a random cohort effect, the model is given by  





, and 𝛿!,… , 𝛿!~!!"𝑀𝑉𝑁(0,𝑇) 
Chen and colleagues developed a method of moments estimator for T.68 However, this 
estimator is only appropriate when studies are independent (see section 3.2.6). We use the 
same framework as Chen to develop an estimator for T without assuming studies are 
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Then, 
𝑉𝑎𝑟 𝑏 = 𝛺 = 𝛴 + 𝐼!×! ⊗ 𝑇 =
𝛴!! + 𝑇 𝛴!" ⋯ 𝛴!!
𝛴!" 𝛴!! + 𝑇 ⋱ ⋮
⋮ ⋱ ⋱ ⋮
𝛴!! ⋯ ⋯ 𝛴!! + 𝑇
 
and 
𝑊!!𝑉𝑎𝑟 𝑏 𝑊! = 𝛴!! + 𝑇,  where 𝛴!!  is the covariance matrix from study 𝑗 
Furthermore, note that 
𝑊!𝑊! =𝑊!!𝑊 = 𝐼!×! for any 𝑗 
Under the null hypothesis of the random effects model,  𝐸 𝑏! − 𝛽 = 0!×! and 
𝐸 𝑏! − 𝛽 𝑏! − 𝛽
! = 𝑉𝑎𝑟 𝑏! − 𝛽 = 𝑉𝑎𝑟 𝑏! = 𝛴!! + 𝑇. Because  𝛽! is an estimator 
of 𝛽 and 𝐸 𝑏! − 𝛽 𝑏! − 𝛽
!
 is a function of T, 𝐸 𝑏! − 𝛽! 𝑏! −  𝛽! ′!!!!  is a 
natural candidate as an estimator for T.  
 First consider 𝐸 𝑏 −𝑊𝛽! 𝑏 −  𝑊𝛽! ′ . By adding and subtracting 𝑊𝛽 to each 
term in the expectation, we can break this expectation up into 4 components: 
𝐸 𝑏 −𝑊𝛽! 𝑏 −  𝑊𝛽! ′ =  𝐸 𝑏 −𝑊𝛽 −𝑊𝛽! +𝑊𝛽 𝑏 −𝑊𝛽 −𝑊𝛽! +𝑊𝛽 ′  




−𝐸 𝑏 −𝑊𝛽 𝑊𝛽! −𝑊𝛽 ′ + 𝐸 𝑊𝛽! −𝑊𝛽 𝑊𝛽! −𝑊𝛽
!
 
I)  𝑬 𝒃−𝑾𝜷 𝒃−𝑾𝜷 !  
Assuming that 𝑏!,… , 𝑏! are unbiased estimators, then 𝐸 𝑏! = 𝐸 𝑏! = ⋯ = 𝐸 𝑏! = 𝛽, 
which implies that  𝐸 𝑏 =𝑊𝛽. Therefore, 𝐸 𝑏 −𝑊𝛽 𝑏 −𝑊𝛽 !  is the central 
second moment of b, so  
𝐸 𝑏 −𝑊𝛽 𝑏 −𝑊𝛽 ! = 𝑉𝑎𝑟 𝑏 = 𝛴 + 𝐼!×! ⊗ 𝑇 
II) 𝑬 𝑾𝜷𝑭 −𝑾𝜷 𝒃−𝑾𝜷 ′  
𝐸 𝑊𝛽! −𝑊𝛽 𝑏 −𝑊𝛽 ′ = 𝐸 𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝑏 −𝑊𝛽 𝑏 −𝑊𝛽 ′  
Note that  
𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝑊𝛽 = 𝐼!×!𝛽 = 𝛽 
Then, 
𝐸 𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝑏 −𝑊𝛽 𝑏 −𝑊𝛽 ′  
= 𝐸 𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝑏 −𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝑊𝛽 𝑏 −𝑊𝛽 ′  
= 𝐸 𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!! 𝑏 −𝑊𝛽 𝑏 −𝑊𝛽 ′  
=𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝐸 𝑏 −𝑊𝛽 𝑏 −𝑊𝛽 ′  
=𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝑉𝑎𝑟(𝑏) 
=𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!(𝛴 + 𝐼!×! ⊗ 𝑇) 
III) 𝑬 𝒃−𝑾𝜷 𝑾𝜷𝑭 −𝑾𝜷 ′  
𝐸 𝑏 −𝑊𝛽 𝑊𝛽! −𝑊𝛽 ′ = 𝐸 𝑊𝛽! −𝑊𝛽 𝑏 −𝑊𝛽 ′ ′ 




Because 𝛴 and T are covariance matrices, they are symmetric, so 𝛴! = 𝛴 and 𝑇! = 𝑇. 
Therefore,  
𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!! 𝛴 + 𝐼⊗ 𝑇 ! = 𝛴 + 𝐼!×! ⊗ 𝑇 𝛴!!𝑊 𝑊!𝛴!!𝑊 !!𝑊′ 
 
IV) 𝑬 𝑾𝜷𝑭 −𝑾𝜷 𝑾𝜷𝑭 −𝑾𝜷
!
 
𝐸 𝑊𝛽! −𝑊𝛽 𝑊𝛽! −𝑊𝛽
!
 
= 𝐸 𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝑏 −𝑊𝛽 𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝑏 −𝑊𝛽 ′  
=𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝐸 𝑏 −𝑊𝛽 𝑏 −𝑊𝛽 ′ 𝛴!!𝑊 𝑊!𝛴!!𝑊 !!𝑊′ 
=𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!𝑉𝑎𝑟(𝑏)𝛴!!𝑊 𝑊!𝛴!!𝑊 !!𝑊′ 
=𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!(𝛴 + 𝐼!×! ⊗ 𝑇)𝛴!!𝑊 𝑊!𝛴!!𝑊 !!𝑊′  
Let 𝛬 =𝑊 𝑊!𝛴!!𝑊 !!𝑊!𝛴!!. It follows from parts I-IV that 
𝐸 𝑏 −𝑊𝛽! 𝑏 −  𝑊𝛽! ′ = 𝛴 + 𝐼!×! ⊗ 𝑇 − 𝛬 𝛴 + 𝐼!×! ⊗ 𝑇  
− 𝛴 + 𝐼!×!⊗ 𝑇 𝛬′− 𝛬 𝛴 + 𝐼!×! ⊗ 𝑇 𝛬′ 
= (𝐼!"×!" − 𝛬)(𝛴 + 𝐼!×! ⊗ 𝑇)(𝐼!"×!" − 𝛬′) 
Note that 𝐸 𝑏! − 𝛽! 𝑏! − 𝛽!
!
 can be rewritten as 𝑊!!𝐸 𝑏 −𝑊𝛽! 𝑏 −  𝑊𝛽! ′ 𝑊!, 
so,   
𝐸 𝑏! − 𝛽! 𝑏! − 𝛽!
!
=𝑊!′(𝐼!"×!" − 𝛬)(𝛴 + 𝐼!×! ⊗ 𝑇)(𝐼!"×!" − 𝛬′) 𝑊! 













It follows that,   
𝐸 𝑏! − 𝛽! 𝑏! − 𝛽!
!




This means that we can estimate T numerically by choosing 𝑇 such that we minimize: 
𝑏! − 𝛽! 𝑏! − 𝛽!
!




However, it is possible that minimizing this equation will result in an estimate of T which 
is not positive definite. Therefore, we use the Cholesky decomposition of T, 𝑇 = 𝐿𝐿′, and 
choosing 𝐿 such that we minimize the following equation and guarantee that T is positive 
definite. 
𝑏! − 𝛽! 𝑏! − 𝛽!
!
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